Meta-analysis supports association of a functional SNP (rs1801133) in the MTHFR gene with Parkinson's disease

Gene

Volumn 531, Issue 1, 2013, Pages 78-83

  Zhu, Zhi gang ^a   Ai, Qing long ^a   Wang, Wen min ^a   Xiao, Zhi cheng ^a,b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Functional polymorphism; Meta analysis; MRNA expression; MTHFR; Parkinson's disease; Rs1801133

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ALLELE; ARTICLE; ASIA; ENZYME ACTIVITY; ETHNICITY; EUROPE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE MAP; HUMAN; META ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ACMSD; AD; ALZHEIMER'S DISEASE; AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE; CI; CONFIDENCE INTERVAL; FUNCTIONAL POLYMORPHISM; GBA; GENOME-WIDE ASSOCIATION STUDY; GLUCOSIDASE BETA ACID; GWAS; MAPT; MCCC1; META-ANALYSIS; METHYLCROTONOYL-COA CARBOXYLASE 1 (ALPHA); METHYLENETETRAHYDROFOLATE REDUCTASE; MICROTUBULE-ASSOCIATED PROTEIN TAU; MRNA EXPRESSION; MTHFR; ODDS RATIO; OR; PARKINSON'S DISEASE; PD; RS1801133; SERINE THREONINE KINASE 39; SINGLE NUCLEOTIDE POLYMORPHISM; SNCA; SNP; STK39; SYNAPTOTAGMIN XI; SYNUCLEIN ALPHA; SYT11;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); ODDS RATIO; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS;

EID: 84884812524     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.07.034     Document Type: Article

References (34)

1. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
2. Bekris L.M., Mata I.F., Zabetian C.P. The genetics of Parkinson disease. J. Geriatr. Psychiatry Neurol. 2010, 23:228-242.
3. Bialecka M., et al. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenet. Genomics 2012, 22:716-724.
4. Caccamo D., et al. Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neruomol. Med. 2007, 9:249-254.
5. Chango A., et al. The effect of 677C→T and 1298A→C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br. J. Nutr. 2000, 83:593-596.
6. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
7. de Lau L.M., Koudstaal P.J., van Meurs J.B., Uitterlinden A.G., Hofman A., Breteler M.M. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann. Neurol. 2005, 57:927-930.
8. Dorszewska J., et al. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. Acta Neurobiol. Exp. (Wars) 2007, 67:113-129.
9. Duan W., Ladenheim B., Cutler R.G., Kruman I.I., Cadet J.L., Mattson M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 2002, 80:101-110.
10. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control. Clin. Trials 1990, 11:116-128.
11. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
12. Fong C.-S., et al. Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan. Clin. Chim. Acta 2010, 412:332-338.
13. Fung H.C., Scholz S., Matarin M., Simon-Sanchez J., Hernandez D., Britton A. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006, 5:911-916.
14. Gorgone G., et al. Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients. Neruomol. Med. 2012, 14:84-90.
15. Greenamyre J.T., Hastings T.G. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 2004, 304:1120-1122.
16. Hamza T.H., Zabetian C.P., Tenesa A., Laederach A., Montimurro J., Yearout D. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42:781-785.
17. Harmon D.L., Ramsbottom D., Whitehead A.S., Ben-Shlomo Y., Davey-Smith G. The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is not associated with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 62:671.
18. Kruman I.I., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 2000, 20:6920-6926.
19. Kuhn W., et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol. 1998, 40:225-227.
20. Lill C.M., et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 2012, 8:e1002548.
21. Lin J., Yueh K., Liu C., Liu J., Lin S. 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease. Acta Neurol. Taiwan. 2007, 16:150.
22. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003, 26:137-146.
23. Muller T., Werne B., Fowler B., Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999, 354:126-127.
24. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
25. Pankratz N., et al. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann. Neurol. 2012, 71:370-384.
26. Plagnol V., et al. A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet. 2011, 7:e1002142.
27. Religa D., et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci. Lett. 2006, 404:56-60.
28. Simon-Sanchez J., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
29. Stranger B.E., et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 2012, 8:e1002639.
30. Todorović Z., et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J. Neurol. Sci. 2006, 248:56-61.
31. Wullner U., Kolsch H., Linnebank M. Methylenetetrahydrofolate reductase in Parkinson's disease. Ann. Neurol. 2005, 58:972-973.
32. Yang T.P., Beazley C., Montgomery S.B., Dimas A.S., Gutierrez-Arcelus M., Stranger B.E. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010, 26:2474-2476.
33. Yasui K., Kowa H., Nakaso K., Takeshima T., Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000, 55:437-440.
34. Yuan R.-Y., et al. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. J. Neurol. Sci. 2009, 287:64-68.